Literature DB >> 2487538

Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses.

L Carosella1, P Menichelli, M Alimenti, G Zuccala, A Gemma, A Cocchi, P U Carbonin.   

Abstract

Pharmacokinetics and pharmacodynamics of verapamil were studied in 11 elderly subjects (age = 79.67 +/- 4.74 years) and in 11 middle-aged subjects (age = 45 +/- 11.37 years) following intravenous (IV), single oral, and long-term oral administration. Plasma verapamil concentrations were determined using high-pressure liquid chromatography (HPLC). Twenty-four hour dynamic Holter electrocardiographic (ECG) recordings were employed to study heart rate (HR) and P-R interval. No difference in plasma half-life, distribution volume, body clearance, and area under the curve (AUC) was observed between the two groups after IV and oral verapamil administration. Blood pressure (BP) and HR were significantly reduced after verapamil IV administration in the elderly group only (p less than 0.05, p less than 0.01, respectively). After single and long-term oral administration, variable HR and BP responses were observed in both groups. The P-R prolongation following both IV and single oral doses exhibited a delay with respect to the peak plasma concentration, inducing a definite hysteresis loop. The slope of P-R variations (using a linear pharmacodynamic model) was greater in the elderly both after IV and single oral verapamil administration, but statistical significance was obtained only after the single oral dose (p less than 0.05). In the elderly group, after long-term oral administration, there was a significant prolongation of the P-R interval (p less than 0.0001) with respect to the corresponding time point of the 24-hour predrug period. Such variations in pharmacodynamic parameters in the elderly did not, however, cause any clinical problem.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2487538     DOI: 10.1007/bf01858113

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  38 in total

1.  Holford NHG and Sheiner LB "Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models", Clin Pharmacokin 6:429-453 (1981)-The Backstory.

Authors:  Nick Holford
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

Review 2.  Medical therapy in the elderly.

Authors:  J A Herd; A J Wood; J Blumenthal; J E Dougherty; R Harris
Journal:  J Am Coll Cardiol       Date:  1987-08       Impact factor: 24.094

3.  Clinical evaluation of medicines used by the elderly.

Authors:  F E Young
Journal:  Clin Pharmacol Ther       Date:  1987-12       Impact factor: 6.875

4.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

5.  Therapeutic implications of slow-channel blockade in cardiocirculatory disorders.

Authors:  G Ellrodt; C Y Chew; B N Singh
Journal:  Circulation       Date:  1980-10       Impact factor: 29.690

6.  Sustained release verapamil in hypertension. Results from a noninvasive ambulatory blood pressure monitoring and a clinical study.

Authors:  A Nissinen; A Koistinen; J Tuomilehto; S Sundberg; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man.

Authors:  R Padrini; E Barbieri; D Piovan; M Toffoli; A Motta; G P Trevi; M Ferrari
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

9.  The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.

Authors:  R G McAllister; E B Kirsten
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

10.  The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration.

Authors:  J A Dominic; D W Bourne; T G Tan; E B Kirsten; R G McAllister
Journal:  J Cardiovasc Pharmacol       Date:  1981 Jan-Feb       Impact factor: 3.105

View more
  3 in total

Review 1.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Is antiarrhythmic treatment in the elderly different? a review of the specific changes.

Authors:  Vera H M Deneer; Norbert M van Hemel
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 3.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.